Evidence map›Paper›PMID 42604001›Full record

ArticleEClinicalMedicine2026

[

Diego Ferone, Marianne Pavel, Ken Herrmann, Pamela L Kunz, Sten Myrehaug, Daniel Halperin, Beth Chasen, Jaume Capdevila, Amparo García-Burillo, Salvatore Tafuto and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Diego FeroneEndocrinology, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Marianne PavelDepartment of Medicine 1, Uniklinikum Erlangen, and Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Ken HerrmannDepartment of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
Pamela L KunzYale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA.
Sten MyrehaugSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Daniel HalperinMD Anderson Cancer Center, Houston, TX, USA.
Beth ChasenMD Anderson Cancer Center, Houston, TX, USA.
Jaume CapdevilaDepartment of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Amparo García-BurilloNuclear Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Salvatore TafutoSarcoma and Rare Tumors Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, Naples, Italy.
Secondo LastoriaDivision of Nuclear Medicine, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, Naples, Italy.
Do-Youn OhSeoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea.
Changhoon YooAsan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Stephen FalkBristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Thorvardur R HalfdanarsonMayo Clinic, Rochester, MN, USA.
Maddalena SansoviniIRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy.
Laura GerardEdouard Herriot University Hospital, Hospices Civils de Lyon, Lyon, France.
Emmanuel DeshayesUnicancer, Montpellier Cancer Institute (ICM), Montpellier University, Montpellier, France.
Angelina FiliceAUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy.
Ilya FolitarNovartis Pharma AG, Basel, Switzerland.
Yufen ZhangNovartis Pharmaceuticals Corp, East Hanover, NJ, USA.
Wouter W de HerderErasmus MC and Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Simron SinghSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In the phase 3 NETTER-2 study, first-line [ Methods: In this open-label, parallel-group study, patients from nine countries were randomised 2:1 to receive four cycles of Findings: Between Jan 22, 2020, and Oct 13, 2022, 261 patients were screened; 35 were excluded due to screen failure, and 226 were randomised. Interpretation: These findings support the use of first-line Funding: Advanced Accelerator Applications, a Novartis Company.

Indexed as

177Lu-DOTATATE[177Lu]Lu-DOTA-TATEEfficacy analysesGastroenteropancreatic neuroendocrine tumoursSubgroup analyses

Identifiers

PMID42604001
PMCPMC13476574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.